Skip to main content

Yubo International Biotech Limited (YBGJ)

New York Stock Exchange Healthcare Medical - Instruments & SuppliesView data quality →
30.9Poor

ValueMarkers Composite Index

Top 0%#44,516 of 44,707

DCF data not available

Piotroski
4/9
Neutral
Beneish
-10.00
Low Risk
Altman
-20.02
Distress
DCF Value
-
N/A
ROIC
57.8%
Strong
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Yubo International Biotech Limited (YBGJ) — VMCI valuation read

Yubo International Biotech Limited (YBGJ) carries a VMCI composite of 31/100, 19 points below the Healthcare sector median of 50. Among mid-cap names, that gap places YBGJ in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The YBGJ insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads YBGJ trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 0.5x leaves covenant headroom, the line to track on Yubo International Biotech Limited's next 10-Q.

YBGJ rose 2.0% over the trailing 7 days, with a +1.7% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in YBGJ’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.